PreGen-Plus Not Covered
Following reconsideration of the current NCD for colorectal cancer screening, CMS says it will not expand the colorectal cancer screening benefit to include coverage of PreGen-Plus, a commercially available screening DNA stool test. CMS says the Food and Drug Administration (FDA) has determined this test requires premarket review and approval. CMS says a subsequent request for reconsideration will be considered once FDA approval is obtained. You can read all about this NCD in CMS Transmittal 89, and in the MLN Matters article MM6145.
Latest posts by admin aapc (see all)
- Message From Your Region 7 Representatives | October 2018 - October 24, 2018
- Message From Your Region 6 Representatives | October 2018 - October 24, 2018
- Message From Your Region 5 Representatives | October 2018 - October 24, 2018